JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, A. E.
Right arrow Articles by Silverman, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, A. E.
Right arrow Articles by Silverman, J. A.

Vol. 286, Issue 3, 1439-1445, September 1998

Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein

Annice E. Kim, Jay M. Dintaman, David S. Waddell and Jeffrey A. Silverman

Drug Transport Division, AvMax, Inc., Berkeley, California

Saquinavir, a peptidomimetic HIV protease inhibitor, has been shown to be effective in reducing patient viral load and reducing mortality. In this report we investigated whether saquinavir is a substrate for the multidrug resistance transporter P-glycoprotein (P-gp), which may reduce the effective intracellular concentration of the drug. G185 cells, which highly express P-gp, are resistant to saquinavir-mediated cytotoxicity, and co-administration of cyclosporine reversed this resistance. Saquinavir and saquinavir mesylate inhibited basolateral to apical transport of the fluorescent dye rhodamine 123 in a polarized epithelial transport assay, a result that suggests competition of these drugs for the P-gp transporter. Finally, we measured specific, directional transport of saquinavir and saquinavir mesylate in an epithelial monolayer model. Transport in the basolateral to apical direction was 3-fold greater than apical to basolateral flux for both saquinavir and saquinavir mesylate and was blocked by co-incubation with the established P-gp reversal agents cyclosporine and verapamil. These data provide evidence that saquinavir is a substrate for the P-gp transporter and suggest that this protein may affect intracellular accumulation of the drug and contribute to its poor oral bioavailability.

0022-3565/98/2863-1439$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
H. Zhang, X. Wu, H. Wang, A. M. Mikheev, Q. Mao, and J. D. Unadkat
Effect of Pregnancy on Cytochrome P450 3a and P-Glycoprotein Expression and Activity in the Mouse: Mechanisms, Tissue Specificity, and Time Course
Mol. Pharmacol., September 1, 2008; 74(3): 714 - 723.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
O. Janneh, E. Jones, B. Chandler, A. Owen, and S. H. Khoo
Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes
J. Antimicrob. Chemother., November 1, 2007; 60(5): 987 - 993.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. W. Chinn, J. M. Gow, M. M. Tse, S. L. Becker, and D. L. Kroetz
Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein
J. Antimicrob. Chemother., July 1, 2007; 60(1): 61 - 67.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Boffito, D. Maitland, L. Dickinson, D. Back, A. Hill, C. Fletcher, G. Moyle, M. Nelson, B. Gazzard, and A. Pozniak
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
J. Antimicrob. Chemother., April 1, 2005; 55(4): 542 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
K. F. K. Ejendal and C. A. Hrycyna
Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A
Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. J. Sinko, J. R. Kunta, H. H. Usansky, and B. A. Perry
Differentiation of Gut and Hepatic First Pass Metabolism and Secretion of Saquinavir in Ported Rabbits
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 359 - 366.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Gupta, Y. Zhang, J. D. Unadkat, and Q. Mao
HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 334 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. U. C. Sankatsing, J. H. Beijnen, A. H. Schinkel, J. M. A. Lange, and J. M. Prins
P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1073 - 1081.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. J. Mouly, M. F. Paine, and P. B. Watkins
Contributions of CYP3A4, P-glycoprotein, and Serum Protein Binding to the Intestinal First-Pass Extraction of Saquinavir
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 941 - 948.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Trout, F. Mentre, X. Panhard, A. Kodjo, L. Escaut, P. Pernet, J.-G. Gobert, D. Vittecoq, A.-L. Knellwolf, C. Caulin, et al.
Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and/or Wasting Syndrome
Antimicrob. Agents Chemother., February 1, 2004; 48(2): 538 - 545.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. T. Huisman, J. W. Smit, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel
Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with Ritonavir
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 596 - 602.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Oncologist, December 1, 2002; 7(6): 516 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. C. Williams, A. Liu, G. Knipp, and P. J. Sinko
Direct Evidence that Saquinavir Is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2)
Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3456 - 3462.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. R. Meaden, P. G. Hoggard, P. Newton, J. F. Tjia, D. Aldam, D. Cornforth, J. Lloyd, I. Williams, D. J. Back, and S. H. Khoo
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals
J. Antimicrob. Chemother., October 1, 2002; 50(4): 583 - 588.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. Piccinini, A. Foli, G. Comolli, J. Lisziewicz, and F. Lori
Complementary Antiviral Efficacy of Hydroxyurea and Protease Inhibitors in Human Immunodeficiency Virus-Infected Dendritic Cells and Lymphocytes
J. Virol., March 1, 2002; 76(5): 2274 - 2278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Murren
Modulating Multidrug Resistance: Can We Target this Therapy?
Clin. Cancer Res., March 1, 2002; 8(3): 633 - 635.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Lee, L. Schlichter, M. Bendayan, and R. Bendayan
Functional Expression of P-glycoprotein in Rat Brain Microglia
J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 204 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. T. Huisman, J. W. Smit, H. R. Wiltshire, R. M. W. Hoetelmans, Jos. H. Beijnen, and A. H. Schinkel
P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir
Mol. Pharmacol., April 1, 2001; 59(4): 806 - 813.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
J. W. Holladay, M. J. Dewey, B. B. Michniak, H. Wiltshire, D. L. Halberg, P. Weigl, Z. Liang, K. Halifax, W. E. Lindup, and D. J. Back
Elevated Alpha-1-Acid Glycoprotein Reduces the Volume of Distribution and Systemic Clearance of Saquinavir
Drug Metab. Dispos., March 1, 2001; 29(3): 299 - 303.
[Abstract] [Full Text]

Home page
 Sex. Transm. Infect.Home page
S. Taylor and A. S Pereira
Antiretroviral drug concentrations in semen of HIV-1 infected men
Sex Transm Inf, February 1, 2001; 77(1): 4 - 11.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Lee, A. J. P. Klein-Szanto, and G. D. Kruh
Analysis of the MRP4 Drug Resistance Profile in Transfected NIH3T3 Cells
J Natl Cancer Inst, December 6, 2000; 92(23): 1934 - 1940.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. F. Choo, B. Leake, C. Wandel, H. Imamura, A. J. J. Wood, G. R. Wilkinson, and R. B. Kim
Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes
Drug Metab. Dispos., June 1, 2000; 28(6): 655 - 660.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
L. Zhang, W. Gorset, C. B. Washington, T. F. Blaschke, D. L. Kroetz, and K. M. Giacomini
Interactions of HIV Protease Inhibitors with a Human Organic Cation Transporter in a Mammalian Expression System
Drug Metab. Dispos., March 1, 2000; 28(3): 329 - 334.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.